Zevra Therapeutics（纳斯达克代码：ZVRA）今日宣布，公司已成功签署一项分销协议，旨在显著提升其核心产品Miplyffa®在治疗尼曼匹克病C型（NPC）领域的市场覆盖范围。该协议的落地预计将优化药物供应链，为更多NPC患者提供便捷的治疗选择。此次战略合作标志着Zevra Therapeutics在推动罕见病疗法普及方面迈出关键一步，有望进一步巩固其在专科治疗领域的市场地位。
Zevra Therapeutics（纳斯达克代码：ZVRA）今日宣布，公司已成功签署一项分销协议，旨在显著提升其核心产品Miplyffa®在治疗尼曼匹克病C型（NPC）领域的市场覆盖范围。该协议的落地预计将优化药物供应链，为更多NPC患者提供便捷的治疗选择。此次战略合作标志着Zevra Therapeutics在推动罕见病疗法普及方面迈出关键一步，有望进一步巩固其在专科治疗领域的市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.